VIGABATRIN — TEVA PHARMS USA, approved 2026-03-18 (ANDA209822).
10,159 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.